How should low sex hormone‑binding globulin (SHBG) be evaluated and managed in a woman?

Low Sex Hormone-Binding Globulin in Women: Evaluation and Management

Low SHBG in women should prompt immediate evaluation for insulin resistance, metabolic syndrome, and polycystic ovary syndrome (PCOS), as low SHBG is strongly associated with hyperandrogenism, cardiovascular risk, and impaired glucose metabolism.

Initial Clinical Assessment

When encountering low SHBG in a woman, focus your history and examination on:

• Menstrual patterns: Document cycle length, regularity, and any amenorrhea or oligomenorrhea (cycles >35 days) 1
• Hyperandrogenic signs: Assess for hirsutism using Ferriman-Gallwey scoring, male-pattern hair distribution, acne, and androgenic alopecia 1
• Metabolic indicators: Calculate BMI and waist-to-hip ratio (WHR >0.9 indicates truncal obesity) 1
• Weight history: Recent weight gain is a key trigger for PCOS development in women with polycystic ovaries 1

Understanding the Pathophysiology

Low SHBG increases bioavailable androgens, creating a vicious cycle of hyperandrogenism and metabolic dysfunction 2. The mechanism involves:

• Insulin and insulin-like growth factor-1 directly suppress hepatic SHBG production 3, 4
• Lower SHBG increases free testosterone despite normal total testosterone 4
• This drives progression of ovarian pathology, anovulation, and PCOS phenotype 2

Importantly, SHBG correlates negatively with body mass index, central adiposity, and fasting insulin levels 3, 4. Women with PCOS show different SHBG-insulin relationships compared to healthy women 4.

Laboratory Evaluation Algorithm

First-Line Testing (Day 3-6 of menstrual cycle):

1. Total testosterone - primary screening test 5
2. SHBG - to calculate free androgen index (FAI = total testosterone/SHBG) 6, 7
3. LH and FSH - LH/FSH ratio >2 suggests PCOS 1
4. Fasting glucose and insulin - glucose/insulin ratio >4 suggests reduced insulin sensitivity 1
5. Prolactin - morning resting levels (>20 μg/L abnormal) 1

Second-Line Testing if indicated:

• Mid-luteal progesterone (<6 nmol/L indicates anovulation) 1
• DHEAS - if testosterone is twice upper limit of normal (>600 mg/dL suggests adrenal adenoma) 5
• 17-hydroxyprogesterone - to exclude 21-hydroxylase deficiency 7
• Pelvic ultrasound - transvaginal preferred, looking for >10 peripheral cysts 2-8mm diameter 1

Critical Diagnostic Considerations

A cutoff value of 51.90 nM should identify low SHBG in Asian women with PCOS 8. However, reference ranges vary by laboratory and ethnicity 9. In the US population, low SHBG is defined as:

• Women <30 years: <14.5 nmol/L
• Women ≥30 years: <21.9 nmol/L 9

Common Pitfall:

Normal total testosterone with clear hyperandrogenic symptoms requires careful interpretation 5. SHBG is typically reduced with obesity, metabolic syndrome, or family history of diabetes 5. Calculate free testosterone or FAI rather than relying on total testosterone alone 7.

Risk Stratification

Women with low SHBG face increased risk for:

• Impaired glucose metabolism: Low SHBG predicts insulin resistance (AUC 0.706), impaired fasting glucose (AUC 0.674), and type 2 diabetes (AUC 0.674) 8
• Cardiovascular disease: Low SHBG independently associates with CVD risk and coronary mortality 6
• PCOS complications: Lower SHBG correlates with higher free testosterone, worse hirsutism, and anovulation 4

The combination of low SHBG with insulin resistance creates the highest risk profile 6, 8.

Management Strategy

1. Address Underlying Metabolic Dysfunction

Weight reduction is the primary intervention for obese women with low SHBG and hyperandrogenism 4. Calorie restriction:

• Reduces serum insulin
• Increases SHBG production
• Decreases free testosterone
• Improves both anovulation and hirsutism 4

Note: Isocaloric low-fat diets without calorie restriction do not significantly affect SHBG 4.

2. Medication Considerations

Certain antiepileptic drugs (carbamazepine, phenobarbital, phenytoin) induce hepatic cytochrome P450, increasing SHBG production and reducing bioavailable sex hormones 1. Conversely, valproate may worsen hyperandrogenism 1.

Oral contraceptives containing estrogen increase SHBG 6, 10, but third-generation progestins and drospirenone produce higher SHBG levels than second-generation progestins 10.

3. Monitoring and Follow-up

For women over 35 with hyperandrogenic symptoms, hyperandrogenemia may not be demonstrable as ovarian androgen production decreases with age, but hirsutism persists 7. Continue monitoring for metabolic and cardiovascular complications regardless of androgen levels.

4. Specialist Referral

Refer to endocrinology or gynecology when:

• Testosterone is twice the upper limit of normal (evaluate for androgen-secreting tumor) 5
• DHEAS >600 mg/dL (adrenal adenoma concern) 5
• Abnormal hormone levels with signs of ovarian dysfunction 11
• Infertility after 12 months of unprotected intercourse 1

Clinical Implications

Low SHBG should be recognized as both a biomarker and potential therapeutic target 2, 12. It reflects hepatic metabolic dysfunction and predicts future diabetes and cardiovascular disease risk 6, 3, 12. Early identification allows intervention before irreversible complications develop.

The evidence strongly supports that SHBG measurement provides more clinical utility than total testosterone alone in evaluating women with suspected hyperandrogenism or metabolic dysfunction 3, 12, 13.